Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium-177-DOTA-cetuximab
- Development stage
- Unknown
- Lead developer
- Fremantle Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lutetium-177-DOTA-cetuximab (¹⁷⁷Lu-DOTA-cetuximab) is an investigational radioimmunotherapy (RIT) agent consisting of cetuximab, a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), conjugated to the macrocyclic chelator DOTA and radiolabeled with the beta-emitting radionuclide lutetium-177. By binding to EGFR, which is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC), the agent delivers targeted cytotoxic beta radiation directly to tumor cells. It is being evaluated in a Phase 0/1 pilot theranostic clinical study (The ReCHANCE Study) led by Dr. Timothy Marr at Fremantle Hospital for patients with advanced HNSCC who have exhausted standard surgical and radiotherapy options.
- Other names
- 177Lu-DOTA-cetuximab177Lu-cetuximablutetium-177-cetuximablutetium177-cetuximablutetium 177-cetuximab177Lu-Cet[177Lu]Lu-DOTA-cetuximab
02
Targets
Beyond the preview
Go deeper on lutetium-177-DOTA-cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium-177-DOTA-cetuximab.